BetterMe Rx vs Curex
Two GLP-1 desks, one scoreboard. We put BetterMe Rx and Curex head-to-head on the published Brief Score — the same six factors, scored the same way.
Curex
FDA warning letter, September 2025 — issued to Curex. See the FDA's warning letter database.
The verdict
Curex takes this head-to-head.
Curex scores 86 to 85 on our six-factor Brief Score — Identical $199 pricing on both molecules, an oral route, LegitScript-certified and nationwide.
That doesn't make BetterMe Rx a bad call — it's best for readers who want an accredited desk with an oral route and don't need the rock-bottom price. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| BetterMe Rx | Curex | |
|---|---|---|
| Brief Score | 85/100 (B) | 86/100 (B) |
| Semaglutide | $199/mo | $199/mo |
| Tirzepatide | $299/mo | $199/mo |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Yes |
| On the tracker | Stableprice stable | Stableprice stable |
BetterMe Rx: $199 sema / $299 tirz held at the mid-market line; LegitScript-certified.
Curex: Flat $199 on both molecules; LegitScript-certified and nationwide.
● Not sold on either?
CoreAge Rx tops the whole ranking at 94/100.
The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.